Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | EEF2K | O00418 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263474 | 1.00 | PTGS2 (0.64) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL8536501 | 0.92 | PTGS2 (0.55) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL8536499 | 0.92 | PTGS2 (0.55) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL8822313 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL8822308 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL8532799 | 0.85 | PTGS2 (0.50) | PTGS2PTGS1GAA | |
| SCHEMBL8532801 | 0.85 | PTGS2 (0.50) | PTGS2PTGS1GAA | |
| SCHEMBL9473753 | 0.81 | PTGS2 (0.43) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL9684863 | 0.80 | GAA (0.56) | PTGS2PTGS1CYP1A2CYP2C9GAA | |
| SCHEMBL8991939 | 0.80 | PTGS2 (0.44) | PTGS2PTGS1CYP1A2CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | claimed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | claimed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | claimed |
| JP-6048943-A | — | — | None | — | — | JP | disclosed |
| US-20100234402-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-09-16 | — | — | US | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5691367-A | ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| JP-H0648943-A | THERAPEUTIC MEDICINE FOR I-TYPE DIABETES | UNIV COLORADO FOUND INC | 1994-02-22 | — | — | JP | disclosed |
| US-5216002-A | Using benzyl substituted rhodanine derivatives as pure enantiomeric form | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0525197-A1 | 3-BENZYLIDENE-1-CARBAMOYL-2-PYRROLIDONE ANALOG | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0434394-A2 | Compounds for treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0391644-A2 | Aryl-substituted rhodanine derivatives | ELI LILLY AND COMPANY (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0211670-B1 | DI-T-BUTYLPHENOL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1990-05-09 | — | — | EP | disclosed |
| EP-0211670-A2 | Di-t-butylphenol compounds | ELI LILLY AND COMPANY (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | PTGS2 2815/4885PTGS1 3325/4885CYP1A2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.